PAVmed Inc is a medical device company engaged in advancing a pipeline of medical technologies from concept to commercialization using a business model focused on capital and time efficiency. Its product includes EsoCheck; CarpX; EsoGuard; PortIO; DisappEAR and others. PAVmed Inc is a medical device company engaged in advancing a pipeline of medical technologies from concept to commercialization using a business model focused on capital and time efficiency. Its product includes EsoCheck; CarpX; EsoGuard; PortIO; DisappEAR and others.
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule PR Newswire NEW YORK, Dec. 23, 2024 NEW YORK, Dec. 23, 2024 /PRNewswire/ -- Lucid...
Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters PR Newswire NEW YORK, Dec. 19, 2024 Partnership launched with fully-contracted...
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication PR Newswire NEW YORK, Dec. 11, 2024 Study demonstrates outstanding...
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones PR Newswire NEW YORK, Dec. 3, 2024 New convertible debt...
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test PR Newswire NEW YORK, Nov. 20, 2024 NEW YORK, Nov. 20, 2024 /PRNewswire/...
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum PR Newswire NEW YORK, Nov. 18, 2024 NEW YORK, Nov. 18, 2024 /PRNewswire/...
PAVmed Provides Business Update and Third Quarter 2024 Financial Results PR Newswire NEW YORK, Nov. 14, 2024 Lucid reports record quarterly EsoGuard® revenue and completes clinical evidence...
Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication PR Newswire NEW YORK, Nov. 7...
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers PR Newswire NEW YORK, Nov. 5, 2024 Industry veterans from leading cancer...
PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024 PR Newswire NEW YORK, Oct. 31, 2024 Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, Oct. 31, 2024...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0329 | 5.39255859695 | 0.6101 | 0.8974 | 0.5719 | 586555 | 0.6415355 | CS |
4 | -0.3443 | -34.8728856477 | 0.9873 | 1.25 | 0.5719 | 239250 | 0.74781135 | CS |
12 | -0.627 | -49.3700787402 | 1.27 | 1.3161 | 0.5719 | 102720 | 0.83785488 | CS |
26 | -0.135 | -17.35218509 | 0.778 | 1.89 | 0.5719 | 87938 | 0.96417033 | CS |
52 | -3.247 | -83.470437018 | 3.89 | 4.44 | 0.5719 | 77372 | 1.54922214 | CS |
156 | -41.357 | -98.469047619 | 42 | 43.8 | 0.5719 | 625750 | 15.592701 | CS |
260 | -14.657 | -95.7973856209 | 15.3 | 145.5 | 0.5719 | 1147820 | 47.2481352 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.